- Home
- THQ vs DNA Comparison
THQ vs DNA Comparison
Compare THQ & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THQ
- DNA
- Stock Information
- Founded
- THQ 2014
- DNA 2008
- Country
- THQ United States
- DNA United States
- Employees
- THQ N/A
- DNA N/A
- Industry
- THQ Finance Companies
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THQ Finance
- DNA Health Care
- Exchange
- THQ Nasdaq
- DNA Nasdaq
- Market Cap
- THQ 714.6M
- DNA 731.1M
- IPO Year
- THQ N/A
- DNA N/A
- Fundamental
- Price
- THQ $18.20
- DNA $15.18
- Analyst Decision
- THQ
- DNA Strong Sell
- Analyst Count
- THQ 0
- DNA 1
- Target Price
- THQ N/A
- DNA $9.00
- AVG Volume (30 Days)
- THQ 158.9K
- DNA 1.7M
- Earning Date
- THQ 01-01-0001
- DNA 11-11-2025
- Dividend Yield
- THQ 7.53%
- DNA N/A
- EPS Growth
- THQ N/A
- DNA N/A
- EPS
- THQ N/A
- DNA N/A
- Revenue
- THQ N/A
- DNA $230,815,000.00
- Revenue This Year
- THQ N/A
- DNA N/A
- Revenue Next Year
- THQ N/A
- DNA $14.41
- P/E Ratio
- THQ N/A
- DNA N/A
- Revenue Growth
- THQ N/A
- DNA 25.21
- 52 Week Low
- THQ $15.29
- DNA $5.00
- 52 Week High
- THQ $20.38
- DNA $17.58
- Technical
- Relative Strength Index (RSI)
- THQ 69.60
- DNA 59.30
- Support Level
- THQ $17.98
- DNA $14.63
- Resistance Level
- THQ $18.30
- DNA $17.58
- Average True Range (ATR)
- THQ 0.28
- DNA 1.29
- MACD
- THQ 0.10
- DNA 0.31
- Stochastic Oscillator
- THQ 90.45
- DNA 62.87
About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.